Baudax Bio (NASDAQ:BXRX) reported quarterly losses of $(1.05) per share. This is a 85.38 percent increase over losses of $(7.18) per share from the same period last year.
Europe Approves Biogen’s Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
